Clinical efficacy of two forms of intravenous iron - Saccharated ferric oxide and cideferron - For iron deficiency anemia

Takuya Araki, M. Takaai, A. Miyazaki, S. Ohshima, T. Shibamiya, Tomonori Nakamura, K. Yamamoto

Research output: Contribution to journalArticle

Abstract

Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs. The purpose of this study was to compare and assess the clinical efficacy of two types of intravenous iron injection, saccharated ferric oxide (SFO) and cideferron (CF). Medical records were obtained for 91 unrelated Japanese anemia patients treated with SFO (n = 37) or CF (n = 54) from May 2005 to May 2010 at Gunma University Hospital. Patients treated with blood transfusion, erythropoietin or oral iron were excluded. Hemoglobin (Hb) values measured on day 0, 7 and 14 were used to assess the efficacy of intravenous irons. A significant increase was observed in the mean Hb value by day 14 of administration in both the CF group and SFO group, and the mean Hb increase due to administration of CF for 7 days was comparable to that of SFO for 14 days. Age and sex did not affect improvement of Hb value. CF is fast acting and highly effective compared with SFO for the treatment of iron deficiency anemia. The use of CF may shorten a therapeutic period for iron deficiency anemia, and CF may be feasible for reducing the hospitalization period.

Original languageEnglish
Pages (from-to)1030-1032
Number of pages3
JournalPharmazie
Volume67
Issue number12
DOIs
Publication statusPublished - 2012 Dec
Externally publishedYes

Fingerprint

saccharated ferric oxide
Iron-Deficiency Anemias
Iron
Hemoglobins
Anemia
Erythropoietin
Intravenous Injections
Blood Transfusion
Medical Records
Hospitalization

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Clinical efficacy of two forms of intravenous iron - Saccharated ferric oxide and cideferron - For iron deficiency anemia. / Araki, Takuya; Takaai, M.; Miyazaki, A.; Ohshima, S.; Shibamiya, T.; Nakamura, Tomonori; Yamamoto, K.

In: Pharmazie, Vol. 67, No. 12, 12.2012, p. 1030-1032.

Research output: Contribution to journalArticle

Araki, Takuya ; Takaai, M. ; Miyazaki, A. ; Ohshima, S. ; Shibamiya, T. ; Nakamura, Tomonori ; Yamamoto, K. / Clinical efficacy of two forms of intravenous iron - Saccharated ferric oxide and cideferron - For iron deficiency anemia. In: Pharmazie. 2012 ; Vol. 67, No. 12. pp. 1030-1032.
@article{57ced8522764467a9c8a189a04281ae1,
title = "Clinical efficacy of two forms of intravenous iron - Saccharated ferric oxide and cideferron - For iron deficiency anemia",
abstract = "Over 90{\%} of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs. The purpose of this study was to compare and assess the clinical efficacy of two types of intravenous iron injection, saccharated ferric oxide (SFO) and cideferron (CF). Medical records were obtained for 91 unrelated Japanese anemia patients treated with SFO (n = 37) or CF (n = 54) from May 2005 to May 2010 at Gunma University Hospital. Patients treated with blood transfusion, erythropoietin or oral iron were excluded. Hemoglobin (Hb) values measured on day 0, 7 and 14 were used to assess the efficacy of intravenous irons. A significant increase was observed in the mean Hb value by day 14 of administration in both the CF group and SFO group, and the mean Hb increase due to administration of CF for 7 days was comparable to that of SFO for 14 days. Age and sex did not affect improvement of Hb value. CF is fast acting and highly effective compared with SFO for the treatment of iron deficiency anemia. The use of CF may shorten a therapeutic period for iron deficiency anemia, and CF may be feasible for reducing the hospitalization period.",
author = "Takuya Araki and M. Takaai and A. Miyazaki and S. Ohshima and T. Shibamiya and Tomonori Nakamura and K. Yamamoto",
year = "2012",
month = "12",
doi = "10.1691/ph.2012.2588",
language = "English",
volume = "67",
pages = "1030--1032",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "12",

}

TY - JOUR

T1 - Clinical efficacy of two forms of intravenous iron - Saccharated ferric oxide and cideferron - For iron deficiency anemia

AU - Araki, Takuya

AU - Takaai, M.

AU - Miyazaki, A.

AU - Ohshima, S.

AU - Shibamiya, T.

AU - Nakamura, Tomonori

AU - Yamamoto, K.

PY - 2012/12

Y1 - 2012/12

N2 - Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs. The purpose of this study was to compare and assess the clinical efficacy of two types of intravenous iron injection, saccharated ferric oxide (SFO) and cideferron (CF). Medical records were obtained for 91 unrelated Japanese anemia patients treated with SFO (n = 37) or CF (n = 54) from May 2005 to May 2010 at Gunma University Hospital. Patients treated with blood transfusion, erythropoietin or oral iron were excluded. Hemoglobin (Hb) values measured on day 0, 7 and 14 were used to assess the efficacy of intravenous irons. A significant increase was observed in the mean Hb value by day 14 of administration in both the CF group and SFO group, and the mean Hb increase due to administration of CF for 7 days was comparable to that of SFO for 14 days. Age and sex did not affect improvement of Hb value. CF is fast acting and highly effective compared with SFO for the treatment of iron deficiency anemia. The use of CF may shorten a therapeutic period for iron deficiency anemia, and CF may be feasible for reducing the hospitalization period.

AB - Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs. The purpose of this study was to compare and assess the clinical efficacy of two types of intravenous iron injection, saccharated ferric oxide (SFO) and cideferron (CF). Medical records were obtained for 91 unrelated Japanese anemia patients treated with SFO (n = 37) or CF (n = 54) from May 2005 to May 2010 at Gunma University Hospital. Patients treated with blood transfusion, erythropoietin or oral iron were excluded. Hemoglobin (Hb) values measured on day 0, 7 and 14 were used to assess the efficacy of intravenous irons. A significant increase was observed in the mean Hb value by day 14 of administration in both the CF group and SFO group, and the mean Hb increase due to administration of CF for 7 days was comparable to that of SFO for 14 days. Age and sex did not affect improvement of Hb value. CF is fast acting and highly effective compared with SFO for the treatment of iron deficiency anemia. The use of CF may shorten a therapeutic period for iron deficiency anemia, and CF may be feasible for reducing the hospitalization period.

UR - http://www.scopus.com/inward/record.url?scp=84870327550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870327550&partnerID=8YFLogxK

U2 - 10.1691/ph.2012.2588

DO - 10.1691/ph.2012.2588

M3 - Article

VL - 67

SP - 1030

EP - 1032

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 12

ER -